ALANNA TEMME
ALANNA TEMME is named as a lobbyist in 22 lobbying reports we hold, filed by 1 registrant for 22 clients.
Earlier government jobs, as reported
A lobbying report lists each lobbyist's covered positions: jobs in Congress or the executive branch that the law asks a lobbyist to disclose. Each line is copied as a report states it.
- Legislative Director, U.S. Representative Jon Porter
Registrants and clients
- LMH STRATEGIC SOLUTIONS · 22 reports
Clients: ALKERMES, INC.; ALNYLAM PHARMACEUTICALS, INC.; ARDELYX, INC.; AVADEL PHARMACEUTICALS, PLC; BICYCLE THERAPEUTICS; ERISA INDUSTRY COMMITTEE (ERIC); GLAXOSMITHKLINE LLC; HARMONY BIOSCIENCES; INCYTE CORPORATION; INSMED INCORPORATED; IONIS PHARMACEUTICALS, INC.; MEDICAL DEVICE MANUFACTURERS ASSOCIATION; MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA); NATERA, INC.; NEUROPACE, INC.; PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA; PTC THERAPEUTICS, INC.; REGENXBIO INC.; REZOLUTE, INC.; SAVARA INC.; STEALTH BIOTHERAPEUTICS INC.; UNIVERSITY OF LOUISVILLE HEALTH.
Bills named where this lobbyist is listed, and how the House and the Senate voted
13 bills named in these reports. None of them became law in our record, so no recorded vote is shown. A lobbying report names the houses of Congress and the agencies the lobbyists contacted. It does not say which members or staff they met.
| Bill | Status | How the House and the Senate voted |
|---|---|---|
| H.R. 946ORPHAN Cures Act | Introduced | No recorded vote in our record |
| H.R. 1262Mikaela Naylon Give Kids a Chance Act | Passed the House | No recorded vote in our record |
| H.R. 1492To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. | Introduced | No recorded vote in our record |
| H.R. 1672Maintaining Investments in New Innovation Act | Introduced | No recorded vote in our record |
| H.R. 1691Employee Business Expense Deduction Reinstatement Act of 2025 | Introduced | No recorded vote in our record |
| H.R. 2213Medical Supply Chain Resiliency Act | Introduced | No recorded vote in our record |
| H.R. 4692MAMDANI Act | Introduced | No recorded vote in our record |
| H.R. 5269RESULTS Act | Introduced | No recorded vote in our record |
| S. 574Healthy Poultry Assistance and Indemnification Act of 2025 | Introduced | No recorded vote in our record |
| S. 832EPIC Act of 2025 | Introduced | No recorded vote in our record |
| S. 932Give Kids a Chance Act of 2025 | Introduced | No recorded vote in our record |
| S. 1862ORPHAN Cures Act | Introduced | No recorded vote in our record |
| S. 2355Patients Deserve Price Tags Act | Reported by committee | No recorded vote in our record |
Issues named: Health Issues (13), Pharmacy (10), Medicare/Medicaid (7), Trade (domestic/foreign) (2).
Every report
| Client | Registrant | Kind, as filed | Posted | Report |
|---|---|---|---|---|
| INSMED INCORPORATEDTrade (domestic/foreign) | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| REZOLUTE, INC.Health Issues | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| UNIVERSITY OF LOUISVILLE HEALTHMedicare/Medicaid | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| STEALTH BIOTHERAPEUTICS INC.Health Issues, Pharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| SAVARA INC.Health Issues, Pharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| REGENXBIO INC.Health Issues, Pharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| PTC THERAPEUTICS, INC.Health Issues | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICAPharmacy, Trade (domestic/foreign) | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| NEUROPACE, INC.Medicare/Medicaid | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| NATERA, INC.Medicare/Medicaid | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| MIDSIZED BIOTECH ALLIANCE OF AMERICA (MBAA)Pharmacy, Medicare/Medicaid | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| MEDICAL DEVICE MANUFACTURERS ASSOCIATIONHealth Issues, Medicare/Medicaid | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| IONIS PHARMACEUTICALS, INC.Health Issues | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| INCYTE CORPORATIONHealth Issues, Pharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| HARMONY BIOSCIENCESHealth Issues | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| GLAXOSMITHKLINE LLCHealth Issues, Pharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| ERISA INDUSTRY COMMITTEE (ERIC)Health Issues | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| BICYCLE THERAPEUTICSHealth Issues, Pharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| AVADEL PHARMACEUTICALS, PLCPharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| ARDELYX, INC.Health Issues, Pharmacy | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| ALNYLAM PHARMACEUTICALS, INC.Medicare/Medicaid | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov | |
| ALKERMES, INC.Medicare/Medicaid | LMH STRATEGIC SOLUTIONS | 2nd Quarter - Report | The report on LDA.gov |
Campaign gifts this lobbyist reported
Lobbyists and registrants report their political contributions twice a year (form LD-203). We hold these reports only for contributions to the campaign committees of members who sponsored or cosponsored a bill named in a lobbying report. Any other contribution: Not checked yet.
No contribution report we hold lists a gift from this filer.
Where this comes from
Lobbying Disclosure Act reports (LD-2), LDA.gov. We save our own copy of each page of LDA.gov's list of reports before we read it. These pages were built from our copies on .
2026-Q2: every page of LDA.gov's list saved and read.
A lobbying report states the registrant's income from the client (a lobbying firm) or its own lobbying expenses (an organization lobbying for itself), for the whole quarter and every issue together. A report of less than $5,000, or of no lobbying activity, states no figure. It is not the amount spent on one bill.
Senate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.